Table V.
Title | Count | P-value | Genes |
---|---|---|---|
Pathways in cancer | 31 | 1.03×10−13 | FGF19, E2F1, E2F3, XIAP, KITLG, FOXO1, FASLG, TCF7L2, PTEN, MMP2, TPM3, CDC42, FOS, BCL2, ITGAV, RAC1, FIGF, FGF2, AKT2, FN1, PRKCA, RET, AR, MSH3, BRAF, CBL, CDK6, CDK4, MAPK1, ETS1, PTCH1 |
Neurotrophin signaling pathway | 13 | 3.19×10−6 | YWHAZ, BRAF, FASLG, IRS1, MAPK1, CDC42, BDNF, PSEN1, BCL2, RAC1, NTRK2, NGFR, AKT2 |
Prostate cancer | 11 | 5.85×10−6 | E2F1, MAPK1, E2F3, AR, BRAF, BCL2, CREB1, FOXO1, PTEN, TCF7L2, AKT2 |
Melanoma | 10 | 6.45×10−6 | E2F1, FGF19, MAPK1, E2F3, BRAF, CDK6, CDK4, FGF2, PTEN, AKT2 |
Pancreatic cancer | 10 | 7.26×10−6 | E2F1, CDC42, MAPK1, E2F3, BRAF, RAC1, CDK6, CDK4, FIGF, AKT2 |
Glioma | 9 | 2.14×10−5 | PRKCA, E2F1, MAPK1, E2F3, BRAF, CDK6, CDK4, PTEN, AKT2 |
Focal adhesion | 15 | 2.22×10−5 | PRKCA, CDC42, MAPK1, CAV1, FLT1, BRAF, XIAP, CCND2, BCL2, ITGAV, RAC1, FIGF, PTEN, FN1, AKT2 |
Small cell lung cancer | 10 | 2.60×10−5 | E2F1, E2F3, XIAP, BCL2, ITGAV, CDK6, CDK4, PTEN, FN1, AKT2 |
Non-small cell lung cancer | 8 | 6.29×10−5 | PRKCA, E2F1, MAPK1, E2F3, BRAF, CDK6, CDK4, AKT2 |
Bladder cancer | 7 | 1.24×10−4 | E2F1, MAPK1, E2F3, BRAF, CDK4, FIGF, MMP2 |
MAPK signaling pathway | 15 | 4.72×10−4 | PRKCA, FGF19, BRAF, MAP2K4, FASLG, CDC42, MAPK1, FOS, DUSP4, BDNF, RAC1, NTRK2, GADD45B, FGF2, AKT2 |
Chronic myeloid leukemia | 5.09×10−4 | E2F1, MAPK1, E2F3, BRAF, CBL, CDK6, CDK4, AKT2 | |
Colorectal cancer | 8 | 1.01×10−3 | MAPK1, FOS, MSH3, BRAF, BCL2, RAC1, TCF7L2, AKT2 |
Renal cell carcinoma | 7 | 2.021×10−3 | CDC42, MAPK1, BRAF, ETS1, RAC1, FIGF, AKT2 |
Thyroid cancer | 5 | 2.04×10−3 | MAPK1, RET, BRAF, TCF7L2, TPM3 |
Cell cycle | 9 | 2.47×10−3 | E2F1, CDC6, E2F3, YWHAZ, CCND2, PRKDC, CDK6, CDK4, GADD45B |
p53 signaling pathway | 6 | 9.20×10−3 | CCND2, CDK6, CDK4, GADD45B, CCNG2, PTEN |
The pathway analysis was performed in Kyoto Encyclopedia of Genes and Genomes database and there were 33 available pathways. Among them, 17 signaling pathways were significant (P<0.01).